- Schrödinger recently finalized a transition, separation, and release of claims agreement with its former Chief Commercial Officer and reported continued progress in shifting its platform to a hosted software licensing model, including a 12% year-over-year increase in annual contract value despite lower software revenue during the transition.
- The company has also provided specific 2026 expectations for annual contract value growth and drug discovery revenue, offering investors clearer visibility into how its hosted model and discovery portfolio could reshape its long-term business mix.
- We’ll now examine how Schrödinger’s move to a hosted software licensing model may influence its existing investment narrative and future expectations.
Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
Schrödinger Investment Narrative Recap
To own Schrödinger, you need to believe its physics based software and drug discovery engine can eventually turn recurring contract value and partnered programs into a more stable, higher margin business. The shift to a hosted software model is a key short term catalyst, with 12% annual contract value growth suggesting the transition is progressing. The biggest near term risk remains pressure on software margins and profitability as revenue mix shifts. Recent news does not materially change that balance yet.
The most relevant recent update is Schrödinger’s 2026 outlook for 10% to 15% annual contract value growth and US$55 million to US$65 million in drug discovery revenue. This gives clearer markers to watch as the hosted model scales and as collaborations mature, helping you frame how much progress on recurring software and discovery income might offset ongoing losses and margin compression during the transition.
Yet even with solid ACV growth, investors should be aware that...
Read the full narrative on Schrödinger (it's free!)
Schrödinger's narrative projects $349.6 million revenue and $23.4 million earnings by 2029.
Uncover how Schrödinger's forecasts yield a $20.88 fair value, a 37% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue could reach about US$424,000,000 and earnings near US$78,900,000 by 2029, which is far more upbeat than consensus and could be challenged if competition in AI drug discovery intensifies or if the hosted transition unfolds differently than expected.
Explore 5 other fair value estimates on Schrödinger - why the stock might be worth just $20.88!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Schrödinger research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
- Our free Schrödinger research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Schrödinger's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Find 44 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com